Paulini Marina Ribeiro, Montarele Letícia Ferreira, Pitol Dimitrius Leonardo, Giannocco Gisele, Pereira Bruno Fiorelini, Buchaim Daniela Vieira, Reis Carlos Henrique Bertoni, Buchaim Rogério Leone, Mardegan Issa Joao Paulo
Department of Basic and Oral Biology, University of São Paulo, Ribeirao Preto 14040-904, Brazil.
Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Federal University of São Paulo, Diadema 09972-270, Brazil.
World J Orthop. 2024 Nov 18;15(11):1075-1087. doi: 10.5312/wjo.v15.i11.1075.
In the medical and dental fields, there is a need for studies of new therapeutic approaches for the treatment of bone defects that cause extensive bone loss. Melatonin may be an important endogenous biological factor for bone remodeling, and growth factors may enhance the repair process.
To evaluate the gene expression of cytokines (IL-1β, IL-6, IL-10 and TNF-α), markers of osteoclastogenesis (RANK, RANKL and OPG) and MMPs (MMP-1, MMP-2, MMP-8 and MMP-13) from the treatment of melatonin associated with an osteogenic membrane and rhBMP-2 on the recovery of a bone injury.
Sixty-four rats were used and divided into 9 experimental groups and were formed according to the treatment carried out in the region of the bone lesion, which varied between the combination of 1, 10 and 100 μmol/L of melatonin. Gene Expression analysis was performed using real time-PCR by reading the concentration of total RNA and reverse transcription.
There were differences between groups when compared with clot or scaffold control, and improvement with a higher concentration of melatonin or rhBMP-2. The combination melatonin (1 µg) with 5 μg of rhBMP-2, using the guided bone regeneration technique, demonstrated some effects, albeit mild, on bone repair of critical bone defects.
This indicates that the approach for administering these substances needs to be reassessed, with the goal of ensuring their direct application to the affected area. Therefore, future research must be carried out, seeking to produce materials with these ideal characteristics.
在医学和牙科领域，需要对治疗导致大量骨质流失的骨缺损的新治疗方法进行研究。褪黑素可能是骨重塑的重要内源性生物因子，生长因子可能会增强修复过程。
评估褪黑素与成骨膜及重组人骨形态发生蛋白-2联合治疗对骨损伤恢复过程中细胞因子（白细胞介素-1β、白细胞介素-6、白细胞介素-10和肿瘤坏死因子-α）、破骨细胞生成标志物（核因子κB受体活化因子、核因子κB受体活化因子配体和骨保护素）以及基质金属蛋白酶（基质金属蛋白酶-1、基质金属蛋白酶-2、基质金属蛋白酶-8和基质金属蛋白酶-13）的基因表达情况。
使用64只大鼠，根据骨损伤区域的治疗方法分为9个实验组，治疗方法包括1、10和100μmol/L褪黑素的不同组合。通过读取总RNA浓度并进行逆转录，使用实时聚合酶链反应进行基因表达分析。
与血凝块或支架对照组相比，各实验组之间存在差异，且较高浓度的褪黑素或重组人骨形态发生蛋白-2可促进恢复。采用引导骨再生技术，将1μg褪黑素与5μg重组人骨形态发生蛋白-2联合使用，对临界骨缺损的骨修复有一定作用，尽管作用轻微。
这表明需要重新评估这些物质的给药方式，以确保它们能直接应用于受影响区域。因此，必须开展未来研究，寻求生产具有这些理想特性的材料。
